FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549
-------------	------	-------

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours ner resnonse	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Eisenberg Marcia</u>					Sir	2. Issuer Name and Ticker or Trading Symbol Singular Genomics Systems, Inc. [OMIC]] (Che	elationship deck all applic	able)) Pers	on(s) to Issu		
(Last)	,	irst)	(Middle)				of Earliest 2023	Trans	saction (Mon	th/Day	y/Year)		Officer below)	(give title		Other (specifically below)	pecify		
3010 SCIENCE PARK ROAD					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DII	EGO C	A	92121										2		led by More		orting Persor		
(City)	(S	itate)	(Zip)		Rι	Rule 10b5-1(c) Transaction Indication													
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							to						
		Tal	ole I - Non	n-Deriv	vative	Se	curities	s Ac	quired, D	ispo	sed o	of, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transar Date (Month/Da				Execution Date		Date,	, Transaction Dispose Code (Instr. 5)		rities Acquired (A) or ed Of (D) (Instr. 3, 4 an		5. Amour Securitie Beneficia Owned F Reported	es Form ally (D) of Following (I) (Ir		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership				
									Code	v /	Amount	(A) (D)	or Price	Transact	Reported Transaction(s) (Instr. 3 and 4)			Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, Ty or Exercise (Month/Day/Year) if any				5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	ly	Ownership of Form: E Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				C	Code	v	(A)	(D)	Date Exercisable	Expi Date	iration	Title	Amount (Instr. 4) or Number		,,,(3)				
Stock Option (Right to Buy)	\$0.747	08/04/2023			A		148,000		(1)	08/0)3/2033	Common Stock	148,000	\$0.00	148,000	0	D		

Explanation of Responses:

1. Subject to the Reporting Person's continuing service, 1/3rd of such option grant will vest on the one year anniversary of the date of grant, with the remainder vesting in 24 equal monthly installments thereafter.

Remarks:

/s/ Dalen Meeter, Attorney-in-

08/08/2023

<u>Fact</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.